Paper Details

  1. Home
  2. Paper Details

Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).

Author: FarberH W, HillN S, IeongM H, KlingsE S, KornJ H, SimmsR W

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Most patients with PH secondary to SSc manifest favorable hemodynamic responses to epoprostenol in the short term. Long-term epoprostenol was generally well tolerated and provides a potential therapeutic option for patients with PH secondary to SSc.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the short- and long-term effects of intravenous epoprostenol in patients with pulmonary hypertension (PH) associated with systemic sclerosis (SSc). METHODS: Sixteen patients with SSc-associated PH and New York Heart Association (NYHA) class III or IV symptomatology underwent ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X

データ提供：米国国立医学図書館（NLM）

Systemic Sclerosis-Associated Pulmonary Hypertension: A Search for Effective Treatment

The world of pulmonary hypertension is a complex and challenging one, much like a desert with its hidden dangers. This study investigated the short- and long-term effects of epoprostenol (prostacyclin) in treating pulmonary hypertension (PH) associated with systemic sclerosis (SSc), a rare and debilitating autoimmune disease. The authors aimed to evaluate the efficacy and safety of this medication in improving symptoms and hemodynamic parameters.

Epoprostenol: A Potential Therapeutic Option

The study found that epoprostenol was effective in improving symptoms, exercise tolerance, and hemodynamic parameters in most patients with SSc-associated PH. The positive effects were observed both in the short-term and long-term treatment periods, indicating the potential for this medication to provide sustained benefits for patients.

Hope for Patients with SSc-Associated PH

This research offers hope for patients with SSc-associated PH. The study's findings suggest that epoprostenol can effectively manage symptoms, improve quality of life, and potentially slow disease progression. This discovery is particularly significant for patients with limited treatment options, offering a potential pathway to improved health and well-being.

Dr.Camel's Conclusion

This study highlights the importance of research in rare and complex conditions, offering valuable insights into the potential of epoprostenol to treat SSc-associated PH. It's like finding a hidden oasis in a harsh desert landscape—a beacon of hope for patients seeking relief and improvement.

Date :
  1. Date Completed 2000-01-28
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

10616012

DOI: Digital Object Identifier

10.1002/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X

Related Literature

Article Analysis
・Effects of epoprostenol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.